Top Markets
Coin of the day
Carmell Therapeutics Corporation Carmell Therapeutics Corporation

Carmell Therapeutics Corporation

CTCX
株式のランク #36666
Carmell Therapeutics Corporation (CTCX) specializes in the creation of... Carmell Therapeutics Corporation (CTCX) specializes in the creation of plasma-based bioactive materials (PBMs) aimed at catalyzing tissue regeneration and repair following injury, illness, or the effects of aging. Their flagship product, CT-101, is a versatile accelerant with a dual focus. For orthopedic and dental applications, it's designed to enhance bone healing in cases such as tibia fractures, foot and ankle fusions, spinal fusions, and also serves as a dental bone graft substitute and bone void filler. Furthermore, CT-101 acts as a tissue healing accelerant, addressing conditions like androgenetic alopecia (pattern baldness) and persistent chronic wounds. Established in 2008, the company operates from its headquarters in Pittsburgh, Pennsylvania.
株価
$0.117
最終同期: 2025-04-04
時価総額
$2.45M
変化(1日)
-13.59%
変化(1年)
0.00%
US
取引 Carmell Therapeutics Corporation (CTCX)

カテゴリー

Carmell Therapeutics Corporation(CTCX)の利益
Jun 2026 時点の利益 TTM: $-6.79M
Carmell Therapeutics Corporation の最新の財務報告によると、同社の現在の利益は $-6.79M です。2023 年には $-16.21M の利益を上げ、これは 2022 年の利益 $-9.05M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Carmell Therapeutics Corporation の利益の推移(2021 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $-6.79M -36.81%
2024 $-10.75M -33.68%
2023 $-16.21M 79.04%
2022 $-9.05M 2,647.97%
2021 $-329.38K 0.00%
同業他社の利益
企業 利益 利益の差
$5.27B -77,766.65%
US
$1.95B -28,821.01%
NL
- -
CH
- -
KR
$3.01B -44,355.62%
BE